Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v2.4.0.6
CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)
 3 Months Ended 125 Months Ended
Mar. 31, 2013
Mar. 31, 2012
Mar. 31, 2013
COSTS AND EXPENSES:      
Research and development $ 1,590,613 $ 1,328,314 $ 27,518,338
General and administrative 1,121,703 997,671 14,416,413
Merger costs 0 0 799,133
Total costs and expenses 2,712,316 2,325,985 42,733,884
LOSS FROM OPERATIONS (2,712,316) (2,325,985) (42,733,884)
OTHER INCOME (EXPENSE):      
Grant income 0 0 244,479
Gain/(loss) on revaluation of derivative warrants 6,043 (28,846) (39,969)
Loss on issuance of derivative warrants (744,957) 0 (744,957)
Interest expense, net (2,649) (2,072) (458,109)
Other income 0 0 1,161
Total other expense, net (741,563) (30,918) (997,395)
NET LOSS (3,453,879) (2,356,903) (43,731,279)
DEEMED DIVIDEND ON WARRANTS 0 0 (543,359)
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (3,453,879) $ (2,356,903) $ (44,274,638)
BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE (in dollars per share) $ (0.07) $ (0.06) $ (2.97)
SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS PER COMMON SHARE (in shares) 51,286,886 36,910,217 14,923,994